PharmaSGP Holding has promoted Peter Gerckens to the role of CEO, with effect from 1 January 2025. Gerckens replaces Natalie Weigand, who is stepping down after more than seven years leading the Gräfelfing, Germany-based consumer health firm.
People On The Move: Appointments At PharmaSGP, Stada, NèreS
A round-up of recent consumer health appointments: PharmaSGP names new CEO; Stada appoints Vietnam head; NèreS adds to board.
More from Europe
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
• By
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
More from Health
• By
FDA testing of 95 benzoyl peroxide products due to concerns about elevated benzene detected by third-party testers found 90% with undetectable or extremely low benzene levels.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.